The Danish company developed the most lucrative new drug the world has ever seen. Then America’s Eli Lilly outmaneuvered it ...

The Danish drugmaker also revealed an improved outlook for the year.

Set against the backdrop of a mixed Q2, Novo is eyeing bolt-ons in favour of transformative acquisitions.

Chief Executive Mike Doustdar’s comments come amid sector focus on M&A and after Novo Nordisk made two disclosures in recent ...

By Mrinalika Roy and Mariam Sunny Aug 5 (Reuters) - Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and ...

Novo Nordisk Q2 results: obesity drug growth (Wegovy pill) offsets pricing pressure. Shares fell 6%, but DCF suggests 25% ...

CNBC's Annika Kim Constantino reports on news regarding Novo Nordisk.

The Wegovy maker raised its outlook, but investors focused on pricing pressure, a pill sales miss and another pipeline ...

Novo Nordisk shares plunged on Friday, erasing more than $30 billion in market value after the Danish drugmaker said a ...

Novo Nordisk raises 2025 outlook again on strong GLP-1 sales as Ozempic/Wegovy grow and oral Wegovy surges—get key Q2 ...

A phase 3 trial of Novo Nordisk’s ziltivekimab has missed its primary endpoint, denting the prospects of a molecule analysts tipped to generate blockbuster sales and diversify t ...

"I don't know the needs of the two competitors that are right now trying to talk to each other, but we don't see a need for a ...